Cancer
1st Edition
Published on 14. February 2007
Book
Hardback
XIV, 452 pages
978-3-540-33119-3 (ISBN)
Description
This volume reviews advances in cancer chemotherapy research over the last 10 years and will be of interest to scientists engaged in drug research in the pharmaceutical industry, biotechnology and startup companies, academia and government institutions. Chapters written by leading experts in their field reflect a range of current medicinal chemistry approaches to small molecule drugs, including anti-hormonal therapy, growth factor inhibition, survival signaling, cell cycle inhibition, anti-angiogenics and anti-invasives. Each chapter covers the drug target and biological rationale, chemotypes, clinical status and future prospects in this rapidly developing area of drug research.
More details
Series
Language
English
Place of publication
Berlin
Germany
Publishing group
Springer Berlin
Target group
Professional and scholarly
Research
Illustrations
28 s/w Abbildungen, 4 farbige Abbildungen
XIV, 452 p. 32 illus., 4 illus. in color. With online files/update.
Dimensions
Height: 23.5 cm
Width: 15.5 cm
Weight
1830 gr
ISBN-13
978-3-540-33119-3 (9783540331193)
DOI
10.1007/978-3-540-33120-9
Schweitzer Classification
Other editions
Content
Overview.- Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer.- Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK.- Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic.- Survival Signaling.- Progress in the Development of Agents to Control the Cell Cycle.- HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit.- Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy.- Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy.- Bcr-Abl Kinase Inhibitors.